Information

A Mixed-methods implementation study that assesses specific locations that have the potential to make a significant impact on the introduction of the new TB vaccine for adults and adolescents. This study includes an IGRA Prevalence Study, as well as a Health System Readiness Assessment to evaluate the readiness of health facilities for TB vaccination. This study will provide a holistic approach to understand the factors that influence uptake, informing strategies to maximize acceptance of new vaccines.

• Gates Foundation (sponsor)

• UCSF (Collaborator)

• JHU (Collaborator)

• UBC (IGRA Kit Distributor)

• Lab Biomedis Unpad (Central Lab)

• Lab Terpadu FKUI (Central Lab)
  

Type of Study

Stakeholders Involved

Mixed Method Implementation Study

Background

Despite many notable advancements over the last decade, tuberculosis (TB) remains a persistent global health challenge with 10 million new cases and 1.5 million deaths annually. This shows the need for the rollout and scale-up of an effective and safe TB vaccine for adults and adolescents. With several vaccine trials still on going, however, a significant gap remains in our preparedness for their real-world implementation. One key challenge is different vaccine mechanisms with efficacy tied to individuals’ TB infection (TBI) status. Furthermore, understanding the most preferred, feasible, impactful, and cost-effective implementation strategies to reach adults and adolescents in high TB burden communities with a new TB vaccine will be essential for optimizing their impact.

Gallery